TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02257827

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy.
Study: NCT04083066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab in combination with methotrexate, cytarabine and dexamethasone
Description: Rituximab 375mg/m2D0 is soluble in 0.9% NS concentration 1mg/ml, micro pump is pumped in 4h HD-methotrexate 3.5g/m2 D1 dissolved in 0.9% NS intravenous drip HD-cytarabine 1g/m2 Q12H D2-3 Dissolved in 250ml 5% GS intravenously~Dexamethasone 40mg D1-5 is dissolved in 100ml 5% GS intravenous drip (21 days is a cycle)
Study: NCT00585039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xopenex
Description: will receive xopenex rather than albuterol to treat acute exacerbation
Study: NCT04268771

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Arm A: DRL_RI
Description: Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm B: Rituxan®/Mabthera®
Description: Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion
Study: NCT01636271

Intervention type: DRUG
Intervention: darapladib
Description: darapladib enteric coated tablets 160 mg

Intervention type: DRUG
Intervention: darapladib
Description: darapladib enteric coated tablets 160 mg
Study: NCT03564496

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS Administration during MRI
Description: All participants including healthy controls and MS patients will be given approximately 15 minutes of active tDCS during MRI. The simultaneous tDCS will be performed up to 2 mA dose intensity to determine CMRO2 changes from when the tDCS is on to when the tDCS is off. The stimulation consists of 15-min up to 2 mA tDCS using 5x5 cm electrode sponges with \~30s ramp-up and ramp-down periods.
Study: NCT02634567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training (CWMT)
Description: The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
Study: NCT02320838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 KHz
Description: 5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study: NCT01636271

Intervention type: DRUG
Intervention: placebo
Description: placebo

Intervention type: DRUG
Intervention: placebo
Description: placebo
Study: NCT01700062

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Description: Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Description: Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP
Study: NCT04637503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2, PSMA and CD276 CAR-T cells
Description: infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
Study: NCT03831009

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction internal fixation (ORIF)
Description: Open fracture reduction followed by internal fixation using a plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction internal fixation (ORIF)
Description: Open fracture reduction followed by internal fixation using a plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Conservative treatment involves ankle protection with a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Conservative treatment involves ankle protection with a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
Study: NCT01120808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paper tape
Description: Paper tape assigned to each participant's randomly selected foot.
Study: NCT05031312

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inferior oblique weakening
Description: inferior oblique myectomy versus inferior oblique anterior nasal transposition in superior oblique palsy treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inferior oblique weakening
Description: inferior oblique myectomy versus inferior oblique anterior nasal transposition in superior oblique palsy treatment
Study: NCT03017404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT01914302

Intervention type: DEVICE
Intervention: Easy Touch Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances

Intervention type: DEVICE
Intervention: Glucoject Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances

Intervention type: DEVICE
Intervention: Microlet Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances
Study: NCT01593670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: administered intravenous (IV), 10 mg/m\^2/day over 1 hour on days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 200 mg by mouth (PO) twice a day on days 6-15

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cells
Description: infusion intravenously (IV) over 15 to 60 minutes day 17
Study: NCT00803608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueContour® Insole
Description: Novel designed insole

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care insole
Description: Current Medicare approved A5513 insole
Study: NCT03144661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB062079
Description: In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB062079
Description: In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB062079
Description: In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB062079
Description: In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
Study: NCT01768377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve block with Lidocain
Description: Lidocain 2% topical injection, 0.5 - 1 cc Lidocain 4% topical injection, 3 cc Lidocain 10% topical spray , total dose 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 microgram/Kg BW IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 0.05 mg/kg BW IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.05 mg/kg BW IV infusion
Study: NCT01293916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spica casting
Description: single versus double leg spica casting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spica casting
Description: single versus double leg spica casting
Study: NCT02618291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Geriatric Evaluation (AGE tool)
Description: Yearly administration of the brief assessment tool (BAT). Once the presence of one or more geriatric syndromes is suspected using the brief assessment tool, a management strategy is proposed. It is divided in two distinct steps: 1) perform additional tests to confirm or exclude the diagnosis and 2) to propose specific management attitudes. All proposed attitudes are based on literature review and geriatrician expertise. The FP remains free to follow the proposed attitudes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit.
Study: NCT03805412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEXCOM G6 RT-CGM
Description: CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.
Study: NCT02974686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid
Study: NCT00879307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Use of quetiapine for 16 weeks in acute mania and depression
Study: NCT00708461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight gain prevention
Description: 1. Changes in the food environment that increase the availability of healthy foods and beverages, reduce food and beverage portion sizes, reduce prices on healthy food items, and increase prices on less healthy food items.~2. Changes in the activity environment that increase cues and incentives for walking at work and at home, using stairs, and to increase exposure of employees to information about active recreational opportunities at work and at home.~3. Changes to the environment to increase cues and incentives for regular weight monitoring by providing scales at convenient locations.~4. Changes in the informational environment that increase frequency of exposure of the employee population to accurate information about healthy food and activity choices.
Study: NCT03102996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nephrotrans
Description: Sodium hydrogen carbonate, ATC-Code: A02AH

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsules without active substance.
Study: NCT04208451

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alixir 400 Protect
Description: During 30 days all patients take every day 30ml of Alixir 400 protect
Study: NCT01239810

Intervention type: DRUG
Intervention: Hyaluronic Acid
Description: Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks

Intervention type: DRUG
Intervention: Hyaluronic Acid
Description: Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
Study: NCT02320838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study: NCT02296788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
Study: NCT02284295

Intervention type: OTHER
Intervention: exposure to respirable silica dust
Description: History of exposure to respirable silica dust due to job

Intervention type: OTHER
Intervention: exposure to aromatic hydrocarbons
Description: history of exposure to aromatic hydrocarbons due to job
Study: NCT06517602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation of Moringa oleifera leaf powder
Description: Women in the experimental group were asked to consistently take the prescribed oral hypoglycemic therapy and to maintain their lifestyle and eating habits. In addition, for the duration of the study (3 months), the experimental group was provided with 10 g of Moringa oleifera leaf powder daily to be consumed with main meals.
Study: NCT02453867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced immunosuppression
Description: Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels \> 5ng/ml) Stop mycophenolate at month 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is used in both the acitve comparator arm and the interventional arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus is used in both the acitve comparator arm and the interventional arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate
Description: Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate
Description: Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
Study: NCT00998582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Description: Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
Study: NCT02898064

Intervention type: DEVICE
Group type: OTHER
Intervention: thoracolumbosacral orthosis or cervicothoracolumbar orthosis
Description: An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
Study: NCT00430638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide, if necessary
Description: olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets administered for once daily for 12 weeks
Study: NCT00209495

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin; Dexamethasone
Description: Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin; Dexamethasone
Description: Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin; Dexamethasone
Description: Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
Study: NCT01799213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg po QD
Description: Eligible subjects will be take Meloxicam 15 mg po QD

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks
Study: NCT01116765

Intervention type: OTHER
Group type: OTHER
Intervention: no stimulation of the oral structure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stimulation of the oral structure
Study: NCT02941822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Description: Details outlines in the intervention description.
Study: NCT05182983

Intervention type: OTHER
Intervention: Tongue images，coating on the tongue and clinical data
Description: Take photos of the tongue of patients with gastrointestinal diseases and collect clinical information.

Intervention type: OTHER
Intervention: Tongue images，coating on the tongue and clinical data
Description: Take photos of the tongue of patients with gastrointestinal diseases and collect clinical information.
Study: NCT02476851

Intervention type: DEVICE
Group type: OTHER
Intervention: POLFA (Needle Assembly)
Description: Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
Study: NCT03660319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Music Therapy
Description: Experiencing Environmental Music Therapy during wait time in radiation oncology waiting room.
Study: NCT02816346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)
Study: NCT04271930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Awareness Practices for Insomnia
Description: MAP-I is a curriculum-based intervention that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Health Information
Description: A video SHE seminar will serve as active comparator for nonspecific treatment elements that pose rival explanations for the effectiveness of MAP-I.